Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau

Neurobiology of Aging

Volumn 25, Issue 3, 2004, Pages 273-281

  Lewczuk, Piotr ^a   Esselmann, Hermann ^b   Otto, Markus ^b   Maler, Juan Manuel ^a   Henkel, Andreas Wolfram ^a   Henkel, Maria Kerstin ^a   Eikenberg, Oliver ^c   Antz, Christof ^c   Krause, Wolf Rainer ^d   Reulbach, Udo ^a   Kornhuber, Johannes ^d   Wiltfang, Jens ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c ABETA GmbH   (Germany)

^d Dept of Psychiat and Psychotherapy ^*

Author keywords

Alzheimer's dementia; Amyloid beta peptides; Cerebrospinal fluid; Receiver operating characteristic (ROC) analysis; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; TAU PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEASUREMENT; MENTAL DEFICIENCY; NEUROCHEMISTRY; PARAMETER; PATIENT CODING; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 10744229989     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00086-1     Document Type: Article

References (26)

1. Consensus report of the Working Group. Molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19(2):109-16.
2. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J.et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry. 57(8):1994;897-902.
3. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B.et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58(3):2001;373-379.
4. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24(1-3):2001;87-97.
5. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3):1975;189-198.
6. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D.et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55(7):1998;937-945.
7. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143(1):1982;29-36.
8. (1-42) and tau levels in CSF. Neurology. 52(8):1999;1555-1562.
9. Ida N., Hartmann T., Pantel J., Schröder J., Zerfass R., Förstl H.et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271(37):1996;22908-22914.
10. Jensen M., Schröder J., Blomberg M., Engvall B., Pantel J., Ida N. et al. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45(4):1999;504-511.
11. Jensen M., Hartmann T., Engvall B., Wang R., Uljon S.N., Sennvik K.et al. Quantification of Alzheimer amyloid β peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med. 6(4):2000;291-302.
12. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M.et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 54(11 Suppl 5):2000;S4-S9.
13. Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol. Aging. 19(2):1998;139-143.
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M.et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34(7):1984;939-944.
15. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D.et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38(4):1995;643-648.
16. Nishimura T., Takeda M., Shinosaki K., Nishikawa T., Nakamura Y., Yoshida Y.et al. Basic and clinical studies on ApoE gene typing by line probe assay (LiPA) as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20(9):1998;793-799.
17. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J.et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225(3):1997;210-212.
18. Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P.et al. Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 54(5):2000;1099-1102.
19. Reiber H., Peter J.B. Cerebrospinal fluid analysis: disease related data patterns and evaluation programs. J. Neurol. Sci. 184:2001;101-122.
20. (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284(1/2):2000;85-88.
21. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y.et al. Combination assay of CSF tau, Aβ 1-40 and Aβ 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158(2):1998;134-140.
22. Shoji M. Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness. Front. Biosci. 7:2002;d997-d1006.
23. Sjögren M., Gisslen M., Vanmechelen E., Blennow K. Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314(1/2):2001;33-36.
24. (1-42) in dementia disorders. Mech. Ageing Dev. 122(16):2001;2005- 2011.
25. Wiltfang J., Esselmann H., Cupers P., Neumann M., Kretzschmar H., Beyermann M.et al. Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J. Biol. Chem. 276(46):2001;42645-42657.
26. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S.et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81:2002;481-496.